Phase 3 Sjögren’s Results Might Change The Case For Investing In Amgen (AMGN)

Simply Wall St · 1d ago
  • Amgen reported Phase 3 data in November 2026 showing clinically meaningful improvements with dazodalibep in Sjögren's disease and presented extensive new clinical and real-world evidence for Repatha across cardiovascular risk groups, including cost-effectiveness analyses and long-term outcomes.
  • Together, a potential first-in-class autoimmune therapy and reinforced Repatha evidence highlight how Amgen is relying on immunology and cardiometabolic specialties to support its revenue mix and offset pressure on older biologics.
  • The focus now shifts to how Amgen's pre-existing investment narrative around obesity, manufacturing constraints, and legacy erosion intersects with dazodalibep's Phase 3 results.

Scan beyond Amgen and see how other specialists in immunology and cardiometabolic care are priced by reviewing our hand-picked 34 high quality undervalued stocks.

Amgen Investment Narrative Recap

To own Amgen, you need to be comfortable with a story that leans on immunology and cardiometabolic drugs to balance erosion in older biologics and the uncertainty around obesity pipelines. According to AnimalDoctorKwon, an investor in the Simply Wall St Community, the key tension is between legacy product pressure and expectations on newer assets.

The short term catalyst now is whether Amgen can keep executing on its existing franchises while funding obesity and autoimmune programs under a high debt load. The recent dazodalibep and Repatha data support the operating story, although they do not remove manufacturing and policy risk tied to obesity expectations.

Among recent updates, the Phase 3 OASIZ 301 data for dazodalibep matters most for this immunology narrative. A potential first in class CD40L antagonist with positive systemic and symptom outcomes in Sjögren's disease gives Amgen another shot at specialty autoimmune revenue as older brands face pricing and volume pressure.

For catalysts, this readout speaks directly to what AnimalDoctorKwon flags as a structural issue. The thesis that macro obesity demand and regulatory vouchers could carry Amgen looks fragile if Prolia and Enbrel erosion continues. Executing on dazodalibep, alongside Repatha and other specialty launches, becomes a practical counterweight to that concern.

On those numbers, AnimalDoctorKwon frames a fair value of US$359.98 for Amgen, based on a model that assumes revenue grows 7.5% a year and the business eventually settles at a 21.0% profit margin once obesity and autoimmune bets fully feed through.

Uncover why Amgen's fair value indicates a 23% potential downside to its current price, which leaves little room for error.

NasdaqGS:AMGN 1-Year Stock Price Chart
NasdaqGS:AMGN 1-Year Stock Price Chart

Exploring Other Perspectives

The bearish analysts focus on capital intensity rather than obesity hype. Their story is that Amgen’s US$2.6b 2026 capex and exposure to US$100b of 340B discounts could squeeze earnings. Before this Sjögren’s result, the lowest forecasts had revenue roughly flat and profit dropping to US$9.0b by 2029. That is a much harsher script. Use this as a cue to compare multiple narratives and see which assumptions fit your own view.

Explore 5 other Amgen fair value estimates, including one that suggests as much as 23% downside from the current price!

Decide For Yourself

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Amgen?

Once you have a view on Amgen, it helps to zoom out and compare it with other opportunities that fit different risk and income profiles. The Simply Wall St Screener lets you do that quickly by filtering for traits that match how you like to invest.